Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.;Lead Discovery Center GmbH
发明人:
Schultz-Fademrecht, Carsten,Klebl, Bert,Choidas, Axel,Koch, Uwe,Eickhoff, Jan,Wolf, Alexander,Ullrich, Axel
申请号：
AU2011297889
公开号：
AU2011297889A8
申请日:
2011.08.26
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
